The effect of antiallergic treatment with desloratadine-montelukast on salivary glands function in allergic rhinitis.
The aim of this study was to evaluate the possible favorable effect of desloratadine-montelukast combination on salivary glands (SG) function in patients with allergic rhinitis (AR) using SG scintigraphy. The study population consisted of 64 patients with AR and 28 healthy controls: 14 males and 14 females, with mean age 32.3±8.6 years. The patients were divided into two groups: the untreated patients group of 32 patients, 16 males and 16 females, mean age 28.5±5.4 years and the treated group, who received the standard clinically recommended oral dose of montelukast 10mg/d and desloratadine 5mg/d for 6 weeks. This group consisted of 32 patients, 16 males and 16 females, mean age 38.3±8.4 years. All patients and healthy controls underwent SG scintigraphy. After the intravenous injection of technetium-99m pertechnetate, ((99m)Tc-P), dynamic SG scintigraphy was performed for 25min. Using the time-activity curves, the following glandular function parameters were calculated for the parotid and the submandibular SG: uptake ratio, maximum accumulation and ejection fraction. Results showed SG hypofunction. All functional parameters obtained for the untreated patients and for the desloratadine-montelukast treated patients were significantly lower than those in healthy controls (P<0.05). There was no statistically significant difference between treated and untreated patients (P>0.05). In conclusion, our study showed that hypofunction of SG was present in all patients with AR. This hypofunction, as tested by semi-quantitative SG scintigraphy, and also the quality of life did not improve after treatment with montelukast and desloratadine.
Ataturk University, Faculty of Medicine, Department of Nuclear Medicine, 25240 Erzurum, Turkey. ayankursad@gmail.com.
Arif
A
Ayan
Ozgur
O
Yoruk
Bedri
B
Seven
Ebru
E
Orsal
Vahit
V
Mutlu
Berrin
B
Aydin
D000085:Acetates / Q000008:administration & dosage* / Q000009:adverse effects*; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003521:Cyclopropanes; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D011804:Quinolines / Q000008:administration & dosage* / Q000009:adverse effects*; D011877:Radionuclide Imaging; D065631:Rhinitis, Allergic / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D012469:Salivary Glands / Q000000981:diagnostic imaging / Q000187:drug effects; D013440:Sulfides; D016896:Treatment Outcome; D014987:Xerostomia / Q000139:chemically induced* / Q000000981:diagnostic imaging*
D000085:Acetates; D018926:Anti-Allergic Agents; D003521:Cyclopropanes; D039563:Histamine H1 Antagonists, Non-Sedating; D011804:Quinolines; D013440:Sulfides; D017336:Loratadine; C121345:desloratadine; C093875:montelukast